Results 21 to 30 of about 1,472 (172)

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates

Frontiers in Microbiology, 2022
In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus
Weiliang Zeng, Xiaotuan Zhang, Yan Liu, Yi Zhang, Mengxin Xu, Sipei Wang, Yao Sun, Tieli Zhou, Lijiang Chen   +8 more
doaj   +1 more source

Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial

Frontiers in Medicine, 2023
IntroductionThe 2019 American Thoracic Society/Infectious Disease Society of America guidelines recommend respiratory fluoroquinolones to treat community-acquired bacterial pneumonia (CABP) in adults with comorbidities.
George D. Rodriguez, George D. Rodriguez, Nathan Warren, Roman Yashayev, Surya Chitra, Maria Amodio-Groton, Kelly Wright   +6 more
doaj   +1 more source

Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease

mSphere, 2023
Mycobacteroides abscessus is an opportunistic pathogen in people with structural lung conditions such as bronchiectasis, chronic obstructive pulmonary disease, and cystic fibrosis. Pulmonary M.
Binayak Rimal, Danielle A. Nicklas, Chandra M. Panthi, Christopher K. Lippincott, Daniel C. Belz, Elisa H. Ignatius, Daniel H. Deck, Alisa W. Serio, Gyanu Lamichhane   +8 more
doaj   +1 more source

Omadacycline [PDF]

Hospital Pharmacy, 2019
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
openaire   +2 more sources

Microbiology and Preclinical Review of Omadacycline [PDF]

Clinical Infectious Diseases, 2019
AbstractOmadacycline is a novel aminomethylcycline antimicrobial and semisynthetic derivative of tetracycline. In vitro, omadacycline displays potent activity against gram-positive and many gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococci, vancomycin-resistant Enterococcus,
Karlowsky, James A, Steenbergen, Judith, Zhanel, George G   +2 more
openaire   +2 more sources

Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility

Microbiology Spectrum, 2022
Tetracycline-based combinations are increasingly used for serious carbapenem-nonsusceptible Acinetobacter baumannii (CNSAb) infections given their potent in vitro activity, synergism with other agents, and acceptable toxicity profile.
Taylor Abbey, Alesia Vialichka, Michele Jurkovic, Mark Biagi, Eric Wenzler   +4 more
doaj   +1 more source

Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump

SAGE Open Medicine, 2022
Objective: To investigate compatibility, stability, and microbiologic risk of omadacycline 1 mg/mL when prepared in an elastomeric infusion pump and stored under refrigeration for 9 days based upon requests for information from healthcare providers ...
Jason Bower, Kelly Wright, Jason Burdette   +2 more
doaj   +1 more source

Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates

Antibiotics, 2022
For decades, the spread of multidrug-resistant (MDR) Acinetobacter baumannii has been rampant in critically ill, hospitalized patients. Traditional antibiotic therapies against this pathogen have been failing, leading to rising concerns over management ...
Manas S. Deolankar, Rachel A. Carr, Rebecca Fliorent, Sean Roh, Henry Fraimow, Valerie J. Carabetta   +5 more
doaj   +1 more source

Omadacycline therapy for Mycobacterium abscessus species infections

Internal Medicine Journal, Volume 53, Issue 12, Page 2257-2263, December 2023., 2023
Abstract Background Antimicrobial resistance and therapy‐related adverse effects make Mycobacterium abscessus treatment challenging. Omadacycline is a novel, bioavailable aminomethylcycline with favourable in vitro activity against M. abscessus. Aims To describe a case report and review the published literature describing outcomes for M.
Paul R. Ingram, Eva E. Jones, Bethwyn Allen, Ronan J. Murray, Terillee J. Keehner, Timothy J. Whitmore   +5 more
wiley   +1 more source

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics

Antimicrobial Agents and Chemotherapy, 2023
Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities.
M. Trang, E. A. Lakota, M. C. Safir, S. M. Bhavnani, L. Friedrich, J. N. Steenbergen, P. C. McGovern, E. Tzanis, C. M. Rubino   +8 more
openaire   +2 more sources